Compare INM & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INM | CNF |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 41.0M |
| IPO Year | N/A | 2018 |
| Metric | INM | CNF |
|---|---|---|
| Price | $1.25 | $5.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 145.5K | 8.6K |
| Earning Date | 02-11-2026 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,798,116.00 | ★ $50,241,013.00 |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $2.36 |
| 52 Week High | $8.27 | $13.90 |
| Indicator | INM | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 61.57 |
| Support Level | $1.18 | $5.90 |
| Resistance Level | $1.35 | $6.20 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 19.44 | 96.55 |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.